Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
How does Microsoft stay ahead in global marketing? Kathleen Mitford, Corporate Vice President at Microsoft, reveals the tech-powered approach that’s powering tomorrow's industries. 🔍 Featured on: How a Digital Twin Modeled Microsoft’s New Campus Tomorrow's World Today - S5E02 – Digital Twins Learn more about this topic: What is a Digital Twin? Microsoft Enables Copilot Studio to Use a Computer on its Own Microsoft Signs Agreement to Scale-Up Carbon Dioxide Removal Microsoft Announces its Fi...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
